{"id":"tegoprazan-amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Taste disturbance"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4297583","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the proton pump to suppress gastric acid secretion, creating an optimal environment for antibiotic efficacy. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target H. pylori through different mechanisms. Together, this triple regimen aims to achieve high eradication rates of H. pylori, which causes peptic ulcer disease and gastritis.","oneSentence":"This triple-therapy combination uses tegoprazan to reduce gastric acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:47.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis"}]},"trialDetails":[{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT06523764","phase":"PHASE4","title":"Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-11-11","conditions":"Helicobacter Pylori Infection Chronic Gastrit","enrollment":208},{"nctId":"NCT06431737","phase":"","title":"Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2024-04-01","conditions":"H.Pylori Infection","enrollment":100},{"nctId":"NCT06682533","phase":"","title":"Tegoprazan- Versus PPI-based H. Pylori Eradication","status":"RECRUITING","sponsor":"Soonchunhyang University Hospital","startDate":"2024-12-01","conditions":"H.Pylori Infection","enrollment":200},{"nctId":"NCT06382493","phase":"NA","title":"Tegoprazan-containing Sequential for H. Pylori","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-02-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT06318104","phase":"PHASE4","title":"Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole","status":"NOT_YET_RECRUITING","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2024-04-19","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT05453994","phase":"","title":"Bismuth for PCAB-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2020-03-01","conditions":"H. Pylori Infection","enrollment":150},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05915871","phase":"PHASE1","title":"Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2023-03-23","conditions":"Healthy","enrollment":22},{"nctId":"NCT05786807","phase":"PHASE4","title":"Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients","status":"UNKNOWN","sponsor":"Wonkwang University Hospital","startDate":"2022-03-07","conditions":"Helicobacter Pylori-positive With Functional Dyspepsia","enrollment":315},{"nctId":"NCT04128917","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-21","conditions":"Helicobacter Pylori Infection","enrollment":102},{"nctId":"NCT04449185","phase":"PHASE4","title":"Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-06-30","conditions":"Dyspepsia","enrollment":60},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tegoprazan triple therapy (TAC)"],"phase":"phase_3","status":"active","brandName":"Tegoprazan/Amoxicillin/Clarithromycin","genericName":"Tegoprazan/Amoxicillin/Clarithromycin","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-therapy combination uses tegoprazan to reduce gastric acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection. Used for Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}